Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078136 | 0.98 | AGXT (0.50) | AGXTBCL2CTSSCTSKGGPS1 | |
| SCHEMBL3836772 | 0.96 | AGXT (0.48) | AGXTBCL2CTSSCTSKGGPS1 | |
| SCHEMBL24005570 | 0.96 | CTSS (0.50) | AGXTBCL2CTSSCTSKGGPS1 | |
| SCHEMBL30777855 | 0.93 | CTSS (0.51) | AGXTBCL2CTSSCTSKKIF11 | |
| SCHEMBL196298 | 0.93 | CTSS (0.51) | AGXTBCL2CTSSCTSKKIF11 | |
| SCHEMBL15238584 | 0.89 | MCL1 (0.49) | BCL2CTSSCTSKBACE1PTGS2 | |
| Formic Acid SCHEMBL27427404 | 0.89 | GPR84 (0.49) | AGXTBCL2GGPS1GPR84BACE1 | |
| SCHEMBL11515483 | 0.88 | PSMB5 (0.49) | AGXTBCL2GGPS1 | |
| SCHEMBL30500519 | 0.88 | PSMB5 (0.49) | AGXTBCL2GGPS1 | |
| SCHEMBL25380703 | 0.87 | BCL2 (0.53) | BCL2CTSSCTSKKIF11HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441901-B2 | Quantum dot ink composition, and quantum dot electroluminescent device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-10-14 | — | — | US | disclosed |
| US-20230287231-A1 | QUANTUM DOT INK COMPOSITION, AND QUANTUM DOT ELECTROLUMINESCENT DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| CN-116606568-A | Quantum dot ink composition and quantum dot electroluminescent device | 三星电子株式会社 | 2023-08-18 | — | — | CN | disclosed |
| US-20230257607-A1 | QUANTUM DOT INK COMPOSITION, AND QUANTUM DOT ELECTROLUMINESCENT DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| CN-115605265-A | Novel compounds for the treatment and/or prevention of diseases, disorders or conditions associated with angiotensin ii | 维科尔药物公司（SE） | 2023-01-13 | — | — | CN | disclosed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| CN-109553712-A | A kind of catalytic component and its catalyst for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109553705-A | A kind of catalytic component and preparation method thereof for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| CN-102245616-A | Method for producing organolithium compound and method for producing substituted aromatic compound | NIPPON SODA CO | 2011-11-16 | — | — | CN | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| EP-0842137-A1 | A PROCESS FOR THE PREPARATION OF CYCLOPROPANE CARBOXYLIC ACIDS AND INTERMEDIATES THEREFOR | CHEMINOVA AGRO A/S (DK) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997003941-A1 | A PROCESS FOR THE PREPARATION OF CYCLOPROPANE CARBOXYLIC ACIDS AND INTERMEDIATES THEREFOR | CHEMINOVA AGRO A/S (DK) | 1997-02-06 | — | — | WO | disclosed |
| CN-1019571-B | Process for preparing biphenyl-n-propylamine derivatives and their salts | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1992-12-23 | — | — | CN | disclosed |
| CN-87104753-A | Prepare the new diphenyl Tri N-Propyl Amine derivative and the method for salt thereof | — | 1988-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | AGXT 564/4885BCL2 2189/4885CTSS 894/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | AGXT 881/4885BCL2 1418/4885CTSS 4429/4885 |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | SLC26A4, OTC, SLC25A20 | AGXT 881/4885BCL2 1418/4885CTSS 4429/4885 |
| US-10004718-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | AGXT 617/4885BCL2 325/4885CTSS 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.